Richard Shelton
Psychiatry · Birmingham, ALNPI 1285726612
Payments from drug & device makers
Across 563 payments — averaging $4341.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1.6M
- Sumitomo Pharma America, Inc.$187K
- Supernus Pharmaceuticals, Inc.$138K
- AbbVie$137K
- Novartis$106K
- Livanova USA, Inc.$103K
- plus $211K from 11 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Scientific Affairs, LLC$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 168 | $1,562,497 |
| Sumitomo Pharma America, Inc. | 122 | $186,990 |
| Supernus Pharmaceuticals, Inc. | 12 | $137,967 |
| AbbVie(2 entities) | 48 | $137,362 |
| Novartis | 6 | $105,550 |
| Livanova USA, Inc. | 83 | $102,685 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $86,050 |
| Acadia Pharmaceuticals Inc | 6 | $55,001 |
| Janssen Scientific Affairs, LLC | 20 | $26,300 |
| Sunovion Pharmaceuticals Inc. | 47 | $22,043 |
| Alfasigma USA, Inc. | 3 | $7,565 |
| Johnson & Johnson | 8 | $6,713 |
| Boehringer Ingelheim International GmbH | 3 | $4,200 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $3,000 |
| Axsome Therapeutics, Inc. | 2 | $80 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| GSK | 1 | $23 |
How this compares
$2,444,059 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Birmingham
- Matthew MacalusoBirmingham$2.8M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Melissa KarrhBirmingham$51K
- Santosh PillaiBirmingham$39K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.